CD63/TSPAN30 recombinant proteins and antibodies

CD63, also known as TSPAN30, is a transmembrane protein belonging to the tetraspanin family, widely expressed in various cell types, including platelets, monocytes, T cells, B cells, and certain tumor cells. As an important molecular marker, CD63 plays a significant role in a variety of biological processes, particularly in cell activation, proliferation, migration, and tumor metastasis. CD63 is also highly expressed in exosomes, making it a crucial target in exosome-related research. Additionally, CD63 is closely associated with tumor immune evasion and immune suppression, positioning it as a potential target in cancer immunotherapy.

CD63 is highly expressed in various tumor cells, especially in malignancies such as melanoma, leukemia, and lymphoma, with its expression levels being closely related to tumor invasiveness, metastasis, and patient prognosis. Studies have shown that CD63 may promote tumor growth and metastasis by regulating immune system mechanisms and immune escape pathways in the tumor microenvironment. Therefore, CD63 is considered a promising target for cancer immunotherapy, particularly in the field of tumor immunotherapy.

Currently, ongoing drug development targeting CD63 primarily focuses on antibody therapies and exosome-related therapeutic research. Monoclonal antibodies targeting CD63 can specifically bind to CD63 on tumor cells, inhibiting tumor cell growth and metastasis. Furthermore, researchers are exploring ways to modulate exosome functions to interfere with CD63’s role in tumor immune evasion, offering new approaches for treating certain types of cancer.
Several pharmaceutical companies have started to focus on the CD63 target and are committed to developing related therapies. Notable global pharmaceutical companies such as Pfizer, Merck, and Novartis have invested heavily in the development of CD63-targeted treatments and have conducted clinical studies. In particular, CD63 targeting shows great potential in immunotherapy for melanoma and other refractory tumors. These companies aim to improve the efficacy of cancer immunotherapy through CD63-targeted therapies, offering new treatment options for cancer patients.

To assist in the development of CD63 targeted therapies, DIMA BIOTECH can now provide a full range of products and services for CD63 targets. Products include CD63 active proteins, CD63 full-length membrane proteins, CD63 reference antibodies, and FC-verified CD63 monoclonal antibodies; services include customized services for antibodies against multiple genus proteins, antibody humanization, and affinity maturation services. In addition, to accelerate the development of CD63 biotherapy, DIMA BIOTECH has also prepared a CD63 target single B cell seed library, from which lead antibody molecules can be obtained in as fast as 28 days; at the same time, we have currently screened out multiple CD63 IgG sequence ready to out-liscensing, and customers can get the molecules for functional evaluation and verification the next day.